Merck & Co., Inc. (NYSE:MRK) Shares Sold by Requisite Capital Management LLC

Requisite Capital Management LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 30.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,184 shares of the company’s stock after selling 956 shares during the period. Requisite Capital Management LLC’s holdings in Merck & Co., Inc. were worth $240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Ruedi Wealth Management Inc. increased its holdings in Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares in the last quarter. AlphaMark Advisors LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at $34,000. Valued Wealth Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $42,000. TFO Wealth Partners LLC grew its stake in shares of Merck & Co., Inc. by 108.1% during the third quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after acquiring an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. acquired a new stake in shares of Merck & Co., Inc. during the third quarter valued at about $50,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock traded down $0.64 during trading on Tuesday, hitting $130.35. 6,550,741 shares of the company’s stock traded hands, compared to its average volume of 8,717,681. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The firm’s fifty day moving average price is $125.24 and its 200 day moving average price is $113.04. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10. The company has a market cap of $330.13 billion, a PE ratio of 935.21, a PEG ratio of 0.52 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same period in the previous year, the business earned $1.62 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. Analysts forecast that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 2,200.00%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MRK. Truist Financial restated a “buy” rating and set a $142.00 target price (up from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. Barclays increased their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, March 27th. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Finally, UBS Group raised their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.71.

Read Our Latest Stock Report on MRK

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.